INCY - INCYTE CORP
94.3
0.180 0.191%
Share volume: 1,479,929
Last Updated: 04-01-2026
Business Services/Services – Research, Development, Testing Labs:
-0.03%
PREVIOUS CLOSE
CHG
CHG%
$94.12
0.18
0.00%
Fundamental analysis
33%
Profitability
0%
Dept financing
42%
Liquidity
75%
Performance
52%
Performance
5 Days
4.39%
1 Month
-5.74%
3 Months
-7.02%
6 Months
9.30%
1 Year
51.29%
2 Year
68.91%
Key data
Stock price
$94.30
DAY RANGE
$93.80 - $95.56
52 WEEK RANGE
$53.56 - $112.29
52 WEEK CHANGE
$50.98
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-29-2025
Company detail
CEO: Herve Hoppenot
Region: US
Website: incyte.com
Employees: 2,320
IPO year: 1993
Issue type: Common Stock
Market: XNAS
Industry: Business Services/Services – Research, Development, Testing Labs
Sector: Services
Region: US
Website: incyte.com
Employees: 2,320
IPO year: 1993
Issue type: Common Stock
Market: XNAS
Industry: Business Services/Services – Research, Development, Testing Labs
Sector: Services
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD) It also develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Recent news